Updating the Role of Carboplatin Added to Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Meta-Analysis
Ida Taglialatela, Beatrice Ruffilli, Benedetta Conte, Francesca D’Avanzo, Valentina Rossi, Simone Nardin, Alessandra Gennari · 2025
Read Updating the Role of Carboplatin Added to Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Meta-Analysis by Ida Taglialatela, Beatrice Ruffilli, Benedetta Conte, Francesca D’Avanzo, Valentina Rossi, Simone Nardin, Alessandra Gennari (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12730687.txt.
Description
Ida Taglialatela and co-authors update a pooled verdict on adding a platinum drug to early breast cancer chemo in 2025. The cancer type lacks three common targets and relapses early. Six trials with over three thousand patients met all rules. Full tumor clearance and disease free survival were the endpoints.
Adding the drug raised full clearance rates clearly. Survival without disease also improved. Spread across trials was low for clearance and modest for survival. Bias checks came out clean. Harms from built up toxicity remain the counterweight, the authors note. They frame the drug as a real gain for this hard cancer. Trial choice and patient fit still guide use.
Catalog record
| CREATOR | Ida Taglialatela, Beatrice Ruffilli, Benedetta Conte, Francesca D’Avanzo, Valentina Rossi, Simone Nardin, Alessandra Gennari |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 29 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |